Credo stock dips 20% despite triple-digit revenue growth; analysts see 30% upside potential.

Credo reported a strong fiscal Q1 2027 with 114.7% revenue growth to $479 million and beat EPS estimates for the eighth consecutive quarter. Despite this, its stock fell nearly 20% in the past month but still trades at a discount compared to peers like Astera Labs and Marvell Technology. Analysts remain optimistic, with a 24/7 Wall St. price target of $218.63, implying over 30% upside. Key risks include customer concentration and potential spending cuts by major clients, but growth in optics and AI infrastructure could drive the stock higher in coming years.

Credo Technology trades at USD 150.98 on Pluang as of Oct 31, 2026 22:41 WIB, down 8.66% in one day. It remains below its 52-week high of USD 302.52. Compared to peers, Astera Labs is priced at USD 258.78 with a 10.90% daily drop, while Marvell Technology trades at USD 196.40, down 10.05% for the day. Pluang users show 64% buy interest in Credo, signaling ongoing investor attention despite recent volatility.